<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Attention-Deficit/Hyperactivity Disorder (ADHD) is connected with high level of psychiatric comorbidity in paediatric population. Depressive disorder is common comorbid disorder co-existing with ADHD. Atomoxetine is worldwide approved for treatment of ADHD in paediatric population; in addition atomoxetine is effective and safe in treatment of some comorbid disorders in ADHD. Pharmacotherapy of depression is limited and residual symptoms are common. Fluoxetine is currently considered to be the gold standard of treatment of depression, but effectiveness of acute phase of treatment is not sufficient. Atomoxetine as a selective noradrenaline reuptake inhibitor or olanzapine as a multi receptors antagonist drug in combination with fluoxetine could be perspective augmented treatment strategy of depression just for their antidepressant effect. The aim of our following study is to evaluate and compare effectiveness and safety of monotherapy and combined/augmented therapy in acute phase of depression treatment in adolescence, as well as introduce complex modern research methodology of effectiveness and safety of treatment. </p></abstract>

Attention-Deficit/Hyperactivity Disorder (ADHD) is connected with high level of psychiatric comorbidity in paediatric population. Depressive disorder is common comorbid disorder co-existing with ADHD. Atomoxetine is worldwide approved for treatment of ADHD in paediatric population; in addition atomoxetine is effective and safe in treatment of some comorbid disorders in ADHD. Pharmacotherapy of depression is limited and residual symptoms are common. Fluoxetine is currently considered to be the gold standard of treatment of depression, but effectiveness of acute phase of treatment is not sufficient. Atomoxetine as a selective noradrenaline reuptake inhibitor or olanzapine as a multi receptors antagonist drug in combination with fluoxetine could be perspective augmented treatment strategy of depression just for their antidepressant effect. The aim of our following study is to evaluate and compare effectiveness and safety of monotherapy and combined/augmented therapy in acute phase of depression treatment in adolescence, as well as introduce complex modern research methodology of effectiveness and safety of treatment.

Is atomoxetine effective in some comorbid mental disorders in ADHD?

Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Clinic of Psychiatry

Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Department of Pharmacology,

Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Clinic of Psychiatry,

Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Department of Pharmacology

Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Biomedical Center Martin,

European Pharmaceutical Journal

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Is atomoxetine effective in some comorbid mental disorders in ADHD?"}

Attention-Deficit/Hyperactivity Disorder (ADHD) is connected with high level of psychiatric comorbidity in paediatric population. Depressive disorder is common...

Is atomoxetine effective in some comorbid mental disorders in ADHD?

Online veröffentlicht: 23. Nov. 2016

Seitenbereich: 29 - 32

Eingereicht: 22. Juni 2016

Akzeptiert: 19. Juli 2016

DOI: https://doi.org/10.1515/afpuc-2016-0003

Schlüsselwörter
ADHD, Atomoxetine, Depressive disorder, Fluoxetine

© by D. Cesneková

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Is atomoxetine effective in some comorbid mental disorders in ADHD?

Online veröffentlicht: 23. Nov. 2016

Seitenbereich: 29 - 32

Eingereicht: 22. Juni 2016

Akzeptiert: 19. Juli 2016

DOI: https://doi.org/10.1515/afpuc-2016-0003

SchlüsselwörterADHD, Atomoxetine, Depressive disorder, Fluoxetine

© by D. Cesneková

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Schlüsselwörter
ADHD, Atomoxetine, Depressive disorder, Fluoxetine